Tdap Vaccine Administration and Recommendations

General Characteristics

The Centers for Disease Control and Prevention recommends that BOOSTRIX, a Tdap vaccine, is available in either prefilled disposable syringes without needles or single-dose vials, and contains aluminum as an adjuvant and no thimerosal 1
The vaccine contains reduced quantities of tetanus toxoid, diphtheria toxoid, and three pertussis antigens, and is administered as a single 0.5mL intramuscular injection 1

The American Academy of Pediatrics recommends that BOOSTRIX is not licensed for use in children younger than 10 years 2

The Centers for Disease Control and Prevention recommends that BOOSTRIX can be used to replace one dose of Td in the 3-dose primary series for adults who have not completed primary immunization 3
The Centers for Disease Control and Prevention recommends that BOOSTRIX can be administered to adults who have close contact with infants <12 months to reduce risk of pertussis transmission 4
The Centers for Disease Control and Prevention recommends that BOOSTRIX is appropriate for use in pertussis outbreak situations 5

The Centers for Disease Control and Prevention recommends that BOOSTRIX is typically administered at least 5 years after the last tetanus and diphtheria toxoid-containing vaccine 6
The Centers for Disease Control and Prevention recommends that in situations with increased risk of pertussis or its complications, intervals shorter than 5 years may be used 5

The Centers for Disease Control and Prevention recommends that BOOSTRIX can be used instead of Td for tetanus prophylaxis in wound management if the person has not previously received Tdap 4
The Centers for Disease Control and Prevention recommends that BOOSTRIX can be safely administered with other vaccines, and simultaneous administration with meningococcal conjugate vaccine is preferred when both are indicated 7
The Centers for Disease Control and Prevention recommends that pregnancy is not considered a contraindication for Tdap vaccination 8

The American Academy of Pediatrics recommends that a history of serious allergic reaction to any component of the vaccine is a contraindication for BOOSTRIX 2
The American Academy of Pediatrics recommends that a history of encephalopathy within 7 days of a previous pertussis-containing vaccine not attributable to another cause is a contraindication for BOOSTRIX 2

The American Academy of Pediatrics reports that pain at the injection site is the most common adverse event, reported in 75% of recipients 1
The American Academy of Pediatrics reports that severe pain occurs in approximately 4.6% of recipients 1

The Centers for Disease Control and Prevention recommends that after receiving BOOSTRIX, subsequent tetanus and diphtheria protection should be maintained with Td boosters every 10 years 8
The Centers for Disease Control and Prevention recommends that BOOSTRIX is not licensed for multiple administrations, and after receipt of BOOSTRIX, subsequent doses should be Td 8